WO1997022360A3 - Control of protein synthesis, and screening method for agents - Google Patents

Control of protein synthesis, and screening method for agents Download PDF

Info

Publication number
WO1997022360A3
WO1997022360A3 PCT/GB1996/003186 GB9603186W WO9722360A3 WO 1997022360 A3 WO1997022360 A3 WO 1997022360A3 GB 9603186 W GB9603186 W GB 9603186W WO 9722360 A3 WO9722360 A3 WO 9722360A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
control
protein synthesis
screening method
pkb
Prior art date
Application number
PCT/GB1996/003186
Other languages
French (fr)
Other versions
WO1997022360A2 (en
Inventor
Philip Cohen
Dario Alessi
Darren Cross
Original Assignee
Medical Res Council
Univ Dundee
Philip Cohen
Dario Alessi
Darren Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9526083.2A external-priority patent/GB9526083D0/en
Priority claimed from GBGB9610272.8A external-priority patent/GB9610272D0/en
Priority claimed from GBGB9615066.9A external-priority patent/GB9615066D0/en
Application filed by Medical Res Council, Univ Dundee, Philip Cohen, Dario Alessi, Darren Cross filed Critical Medical Res Council
Priority to AU12004/97A priority Critical patent/AU1200497A/en
Priority to JP09522599A priority patent/JP2000502097A/en
Priority to EP96943208A priority patent/EP0868195A2/en
Publication of WO1997022360A2 publication Critical patent/WO1997022360A2/en
Publication of WO1997022360A3 publication Critical patent/WO1997022360A3/en
Priority to US11/682,135 priority patent/US7897371B2/en
Priority to US13/021,048 priority patent/US20110275102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for screening for agents capable of affecting the activity of kinases GSK3 and PKB is disclosed. The method involves assessing the phosphorylation of PKB on two amino acids on the PKB molecule particularly.
PCT/GB1996/003186 1995-11-16 1996-12-20 Control of protein synthesis, and screening method for agents WO1997022360A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU12004/97A AU1200497A (en) 1995-12-20 1996-12-20 Control of protein synthesis, and screening method for agents
JP09522599A JP2000502097A (en) 1995-12-20 1996-12-20 Methods for controlling protein synthesis and screening for agonists
EP96943208A EP0868195A2 (en) 1995-12-20 1996-12-20 Control of protein synthesis, and screening method for agents
US11/682,135 US7897371B2 (en) 1995-11-16 2007-03-05 Activation of mutated RAC-PK
US13/021,048 US20110275102A1 (en) 1995-11-16 2011-02-04 Activation of mutated rac-pk

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9526083.2 1995-12-20
GBGB9526083.2A GB9526083D0 (en) 1995-12-20 1995-12-20 Method
GBGB9610272.8A GB9610272D0 (en) 1996-05-16 1996-05-16 Method
GB9610272.8 1996-05-16
GBGB9615066.9A GB9615066D0 (en) 1996-07-18 1996-07-18 Method
GB9615066.9 1996-07-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09091763 A-371-Of-International 1996-12-20
US09/845,667 Continuation US20020065221A1 (en) 1995-11-16 2001-04-30 Control of protein synthesis, and screening method for agents

Publications (2)

Publication Number Publication Date
WO1997022360A2 WO1997022360A2 (en) 1997-06-26
WO1997022360A3 true WO1997022360A3 (en) 1997-07-31

Family

ID=27268041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003186 WO1997022360A2 (en) 1995-11-16 1996-12-20 Control of protein synthesis, and screening method for agents

Country Status (5)

Country Link
EP (1) EP0868195A2 (en)
JP (1) JP2000502097A (en)
AU (1) AU1200497A (en)
CA (1) CA2241080A1 (en)
WO (1) WO1997022360A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525702D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Process for activating a kinase
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU9395098A (en) * 1997-09-26 1999-04-23 Babraham Institute, The Compositions and methods for identifying pkb kinase inhibitors
US6682920B1 (en) 1997-09-26 2004-01-27 Onyx Pharmaceuticals, Inc. Compositions and methods for identifying PKB kinase inhibitors
SE9801530D0 (en) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Ab Method of screening
WO1999064062A1 (en) * 1998-06-08 1999-12-16 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
WO2001037852A2 (en) * 1999-11-23 2001-05-31 Regeneron Pharmaceuticals, Inc. Methods of inhibiting atrophy or promoting hypertrophy
IL153851A0 (en) 2000-07-27 2003-07-31 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
WO2002024941A2 (en) * 2000-09-22 2002-03-28 University Of Dundee Protein kinase regulation
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
JP4394961B2 (en) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Fusion quinoxaline derivatives as inhibitors of AKT activity
JP4451136B2 (en) 2002-04-08 2010-04-14 メルク エンド カムパニー インコーポレーテッド Akt activity inhibitor
US20050182256A1 (en) 2002-04-08 2005-08-18 Duggan Mark E. Inhibitors of akt activity
EP1496896A4 (en) 2002-04-08 2007-10-31 Merck & Co Inc Inhibitors of akt activity
GB0213614D0 (en) 2002-06-13 2002-07-24 Novartis Forschungsstiftlung Z Purified PKB Kinae and uses thereof
CA2501365C (en) 2002-10-30 2011-05-31 Merck & Co., Inc. Inhibitors of akt activity
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
CA2522262A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
DE602004023838D1 (en) 2003-04-24 2009-12-10 Merck & Co Inc HEMMER OF ACT ACTIVITY
CA2522431A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US7354944B2 (en) 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
EP2173728A2 (en) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclic modulators of pkb
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
WO2009125798A1 (en) * 2008-04-09 2009-10-15 萬有製薬株式会社 Method for screening of pharmaceutical candidate substance for treatment of cancer in which hedgehog pathway is activated
EP3529615A1 (en) 2016-10-24 2019-08-28 Novo Nordisk A/S Bioassay for insulin formulations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B. BURGERING ET AL.: "Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.", NATURE, vol. 376, no. 6541, 17 August 1995 (1995-08-17), LONDON, GB, pages 599 - 602, XP002032104 *
D. ALESSI ET AL.: "Mechanism of activation of protein kinase B by insulin and IGF-1.", THE EMBO JOURNAL, vol. 15, no. 23, 2 December 1996 (1996-12-02), OXFORD, GB, pages 6541 - 6551, XP002032108 *
D. ALESSI ET AL.: "Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase.", FEBS LETTERS, vol. 399, no. 3, 16 December 1996 (1996-12-16), AMSTERDAM, NL, pages 333 - 338, XP002032109 *
D. CROSS ET AL.: "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.", NATURE, vol. 378, no. 6559, 21 December 1995 (1995-12-21), LONDON, GB, pages 785 - 789, XP002025954 *
E. SIEGFRIED ET AL.: "Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3.", NATURE, vol. 345, no. 6278, 28 June 1990 (1990-06-28), LONDON, GB, pages 825 - 829, XP002032106 *
H. KONISHI ET AL.: "Molecular cloning of rat RAC protein kinase alpha and beta and their association with protein kinase C gamma.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 1, 30 November 1994 (1994-11-30), DULUTH, MN, USA, pages 817 - 825, XP002032107 *
T. FRANKE ET AL.: "The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.", CELL, vol. 81, no. 5, 2 June 1995 (1995-06-02), CAMBRIDGE, MA, USA, pages 727 - 736, XP002032105 *

Also Published As

Publication number Publication date
CA2241080A1 (en) 1997-06-26
WO1997022360A2 (en) 1997-06-26
EP0868195A2 (en) 1998-10-07
JP2000502097A (en) 2000-02-22
AU1200497A (en) 1997-07-14

Similar Documents

Publication Publication Date Title
WO1997022360A3 (en) Control of protein synthesis, and screening method for agents
SI0868125T1 (en) Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
AU5324996A (en) Protein kinase c inhibitors
AU7436494A (en) Protein isolate having an increased level of isoflavone compound and process for producing the same
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
AU6311696A (en) Recombinant protein having bacteriophage endosialidase enzymatic activity
EP0864647A4 (en) Fructosyl amino acid oxidase, process for producing the same, and method of assaying amadori compounds using the enzyme
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
AU7247896A (en) Protein signature analysis
AU7225396A (en) Method and system for determination of the pressure-volume relationship of the heart
EP1281770A3 (en) Human brain phosphodiesterase and screening method
WO1998005786A3 (en) AFC1 and RCE1:isoprenylated CAAX processing enzymes
AU7727996A (en) Excitatory amino acid derivatives
AU3804995A (en) Melanoma-associated protein
AU3524995A (en) Method for treatment of cancers by regulating the activity of ras proteins
AU6960296A (en) Methods and articles for enhanced protein adsorption and fluid management on surfaces
AU4630297A (en) Map kinases: polypeptides, polynucleotides and uses thereof
AU9257998A (en) Method for enhancing the activity of an enzyme
AU7936698A (en) Method for inferring protein functions with the use of ligand data base
AUPN720195A0 (en) Equine rhinovirus 1 proteins
AU1599299A (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators
WO1999015659A3 (en) Human ubiquitin-conjugating enzymes
WO1999027080A3 (en) Human protein kinase and kinase inhibitors
GB9514722D0 (en) Method
WO1997017448A3 (en) Calcium independent cytosolic phospholipase a2/b enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2241080

Country of ref document: CA

Ref country code: CA

Ref document number: 2241080

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 522599

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996943208

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996943208

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996943208

Country of ref document: EP